Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
Press Release - Accuray Incorporated (ARAY-NASDAQ) |
|
|
“If you are a patient, you should remember that Accuray’s CyberKnife is an alternative to surgery. It’s a non-invasive, painless out-patient procedure. The Cyberknife can treat inoperable tumors, and even if operable, you don’t want to cut open the patient, crack open their rib cage, and deflate their lungs in order to treat a lung tumor or invasively treat a tumor that is wrapped around the spine. It may be inoperable in that case. Our technology offers the means to deliver high doses of radiation...” - Robert E. McNamara (ARAY) (Interview published May 30, 2008) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | SERVICES | HOME PAGE |
|
Neurosurgery Journal Issues Supplement
Dedicated to CyberKnife Radiosurgery Experience
for Brain and Spine Applications The supplement, titled "CyberKnife Stereotactic Robotic Radiosurgery" features 15 papers from seven different countries, focused on brain and spine treatment using the CyberKnife(R) Robotic Radiosurgery System. All papers were subjected to thorough peer review by the editorial board of Neurosurgery and describe a wide range of CyberKnife treatment experiences. These papers highlight experience with the CyberKnife System from studies as large as 1,075 patients and for follow-up periods up to five years or more. The benefits of the CyberKnife System's ability to perform
radiosurgery completely non-invasively, without the need for a head
frame are highlighted in several of the papers, including one by Colombo and his associated authors obtained high rates of tumor control, even for large lesions and lesions near the sensitive brainstem and optic nerves, with low levels of treatment-related complications over an average 30- month follow-up. The authors estimate that the ability to treat in more than one session using the CyberKnife allowed them to treat more than 30 percent of patients that could not have been treated with single-session radiosurgery because the tumors were too large or too close to sensitive structures. "The CyberKnife System has altered the way we think about what
can be treated with radiosurgery. We would not have treated many of
these patients using the previous single-session, frame-based
procedure because of the high risk of complications," said About the CyberKnife(R) Robotic Radiosurgery System The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non- invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames. About Safe Harbor Statement The foregoing may contain certain forward-looking statements that
involve risks and uncertainties, including uncertainties associated
with the medical device industry. Except for the historical
information contained herein, the matters set forth in this press
release, including statements relating to clinical studies,
regulatory review and approval, and commercialization of products
are forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements speak only as of the date the
statements are made and are based on information available at the
time those statements are made and/or management's good faith belief
as of that time with respect to future events. You should not put
undue reliance on any forward-looking statements. Important factors
that could cause actual performance and results to differ materially
from the forward-looking statements we make include: market
acceptance of products; competing products, the combination of our
products with complementary technology; and other risks detailed
from time to time under the heading "Risk Factors" in our report on
Form 10-K for the 2008 fiscal year, as updated from time to time on
Form 10-Q and our other filings with the SOURCE
|
ceocfointerviews.com does not purchase or
make
recommendation on stocks based on the interviews published.